PureTech Health plc American Depositary Shares (PRTC)
FairStock Score: 50/100 — MIXED
Key Financials
| Current Price | $17.38 |
| Market Cap | $426M |
| P/E Ratio | -3.78 |
| ROE | -30.85% |
| Dividend Yield | —% |
| Sector | Healthcare |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
As a Buffett/Graham-style investor, I want a business with durable competitive advantages, honest accounting, and a price below intrinsic value. PureTech Health is a clinical-stage biotech with a market cap of $426 million at the 2026-07-17 close of $17.38. Its pipeline includes LYT-100 in Phase 2 for idiopathic pulmonary fibrosis, LYT-200 in Phase 1/2 for solid tumors and hematological malignancies, and SPT-300 for anxious depression. That is optionality, not a moat; no commercial product or revenue engine is described. The financial picture is weak. At the 2026-07-17 close, FairStock calculations show a negative P/E of -3.78, P/B of 1.35, ROE of -30.85%, ROCE of -10.82%, and D/E of 0.66. The Piotroski F-Score is 1/9, and the Altman Z-Score is 1.49, both warning signs. Revenue growth and profit growth are not available, and the Lynch category is none because there are only 0 years of filed results versus the 3 needed. The shares sit in a 52-week range of $14.50-$19.92 and carry a beta of 0.79. The P/B of 1.35 is not demanding if book value is real and pipeline value is ignored, but a negative P/E means there are no earnings to value. The FairStock Score of 50/100 is neutral. I would need clinical progress and a firmer financial base before calling this a bargain. The price may be fair for a speculative pipeline, but it is not a Graham-style margin of safety.
In plain English: PureTech Health is a biotechnology company working on experimental medicines for lung scarring, cancer, and anxious depression. The business looks weak right now: it is losing money, has weak financial-health signals, and lacks a multi-year filing record. At the 2026-07-17 close of $17.38, the price looks closer to fair than cheap given the risks, though the limited figures make any conclusion tentative.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data as of 2026-07-17 close · note generated 2026-10-15 · model deepseek-flash
Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer